Study Summary
The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this dose, they can test it in future participants to see if it is effective in treating their relapsed/refractory B-cell cell cancers. This study will also look at whether 19(T2)28z1xx CAR T cells work against participants' cancer.
Want to learn more about this trial?
Request More InfoInterventions
19(T2)28z1xx CAR T cellsDRUG
2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | United States |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | United States |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | United States |
| Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) | Commack | New York | United States |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | United States |